MMVSola: A free tool that predicts how new malaria drugs will work in patients
MMVSola: A free tool that predicts how new malaria drugs will work in patients
2020 – present
Our Strategies & Approaches
Mathematical Modelling to Predict Drug Behaviour
Validated, state-of-the-art mathematical algorithms consolidate data from different preclinical experiments, seamlessly translating the results into predictions of both the drug candidate’s exposure and effect on parasite dynamics. This means researchers can make informed decisions about promising compounds much earlier in the development process, without waiting for expensive and time-consuming clinical trials.
Open Access Approach for Global Collaboration
MMVSola is freely available to researchers worldwide, breaking down barriers that traditionally limit access to advanced drug development tools. The tool is built with secure encryption and does not store user data. This open approach enables global collaboration and ensures that research teams of different sizes and resources can access cutting-edge predictive technology.
#Learn more about MMVSola
Reducing Animal Testing and Accelerating Discovery
MMVSola integrates parameters established in the laboratory, including allowing predictions to be made without data from animal efficacy studies. This saves crucial resources, reduces the need for animal models and expedites drug development timelines. The tool can be used as early as the discovery phase, helping researchers identify the most promising compounds before investing in expensive experiments.
Our Key Findings & Impact
Accelerated Malaria Drug Development Globally
All of MMV’s drug discovery projects use the MMVSola tool, enabling the comparison of compounds across the entire portfolio. Since its launch in 2020, the tool has been used by research teams worldwide to evaluate thousands of potential malaria treatments, dramatically speeding up the identification of promising drug candidates.
Recognition for Innovation in Global Health
MMV’s Independent Expert Scientific Advisory Committee (ESAC) awarded MMVSola the Project of the Year 2022 for its outstanding ability to assist discovery teams in estimating human PK and dose for their lead compounds. This recognition highlights the tool’s significant contribution to advancing malaria research and treatment development.
Broader Applications Beyond Malaria
The tool’s PK prediction function can be used not only in malaria, but in other therapeutic areas as well. This means MMVSola’s impact extends beyond malaria to potentially accelerate drug development for other infectious diseases and medical conditions.
Standardised Global Research Approach
The tool promotes the use of standardised drug discovery data, enabling laboratories to collaborate more effectively. This standardisation helps researchers around the world work together more efficiently, sharing insights and avoiding duplication of effort in the fight against malaria.
Our Partners
MMVSola was developed through collaboration between leading institutions and experts in malaria research and drug development.
- Medicines for Malaria Venture (MMV)
- MMV Expert Scientific Advisory Committee
- LSTM Centre for Drugs and Diagnostics (CDD)
- IntiQuan GmbH (modelling and simulation)
- Global network of malaria researchers using the tool
